PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?
Ann Oncol
.
2017 May 1;28(5):914-916.
doi: 10.1093/annonc/mdx104.
Authors
P J Vlachostergios
1
,
A M Molina
1
Affiliation
1
Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, USA.
PMID:
28379379
DOI:
10.1093/annonc/mdx104
No abstract available
Publication types
Editorial
Comment
MeSH terms
Carcinoma, Renal Cell*
Cell Line, Tumor
Humans
Kidney Neoplasms
Phosphatidylinositol 3-Kinases*
Proto-Oncogene Proteins c-akt
Substances
Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins c-akt